# Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

> **NCT05385250** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Karen-Lise Garm Spindler** · enrollment: 100 (estimated)

## Conditions studied

- Anal Cancer
- Radiotherapy Side Effect

## Interventions

- **OTHER:** Bone sparring radiotherapy

## Key facts

- **NCT ID:** NCT05385250
- **Lead sponsor:** Karen-Lise Garm Spindler
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-23
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385250, "Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05385250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*